CSL has warned of a “biotech bubble” amid a frenzy of mergers and acquisition activity across the healthcare sector, the FT reports.
CSL has warned of a “biotech bubble” amid a frenzy of mergers and acquisition activity across the healthcare sector, the FT reports.